Andrew Huberman Peptides: Hypothesized Full Protocol

What Has Andrew Huberman Actually Said About Peptides?

Andrew Huberman has spoken about peptides across multiple Huberman Lab podcast episodes and in guest appearances on other shows. His statements fall into three distinct tiers: compounds he has described using personally, compounds he has discussed mechanistically without confirming personal use, and compounds that informed observers have inferred from the totality of his supplement discussions.

This article uses those tiers explicitly. Where a claim relies on inference rather than a direct Huberman quote, a label reads "INFERRED." Where a direct statement exists, the episode or source is cited.

Tier 1: Compounds Huberman Has Discussed as Personal or Near-Personal Use

In a 2022 Huberman Lab episode on tissue repair, Huberman described BPC-157 as something he had "looked into seriously" and referenced its use for tendon and gut healing. He stopped short of confirming active personal use on that recording, but the discussion was notably first-person in framing.

On PT-141 (bremelanotide), Huberman has been more direct. In his episode on sexual health and libido (released in 2021), he described the melanocortin mechanism of PT-141 and noted it as a compound with "real clinical data." PT-141 is the active ingredient in Vyleesi, which the FDA approved in June 2019 for hypoactive sexual desire disorder in premenopausal women. [1]

Tier 2: Mechanistic Discussions Without Confirmed Personal Use

Huberman has devoted significant podcast time to growth-hormone physiology, including the pulsatile release of GH during slow-wave sleep. In that context he has described growth-hormone secretagogues, including the GHRH-analog class (to which CJC-1295 belongs) and the ghrelin-mimetic class (to which Ipamorelin belongs), as compounds "used in clinical and research settings." He has not, in publicly available recordings, stated he uses either.

Tier 3: INFERRED From Protocol Context

INFERRED: Several clinicians and podcast commentators have noted that Huberman's detailed familiarity with GH secretagogue stacking protocols, combined with his discussions of body composition and recovery, is consistent with personal use of CJC-1295 or Ipamorelin. This remains inference. No direct statement confirms it.

BPC-157: What the Research Shows

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. Its proposed mechanisms include upregulation of growth hormone receptor expression in tendon fibroblasts and modulation of nitric oxide pathways. [2]

Animal Data

The bulk of BPC-157 evidence is in rodent models. A 2018 study in the Journal of Physiology and Pharmacology found accelerated Achilles tendon healing in rats given 10 mcg/kg of BPC-157 intraperitoneally compared to saline controls (P<0.05). [3] A separate rodent study published in PLOS ONE examined gut mucosal repair and found reduced lesion area in BPC-157-treated animals versus controls. [4]

Human Data Gaps

No Phase 3 randomized controlled trial in humans has been completed for BPC-157 as of early 2025. The absence of human trial data means that dose, route of administration, and safety in humans are extrapolated from animal work. The FDA has not approved BPC-157 for any indication, and the agency has flagged concerns about compounded peptide purity. [5]

Typical Discussed Dosing (Research Context Only)

In the animal literature, doses range from 2 mcg/kg to 10 mcg/kg. Human practitioners working with compounded BPC-157 have described subcutaneous doses of 250 mcg to 500 mcg daily or twice daily for 4 to 6-week cycles. These figures appear in clinical case reports and practitioner forums rather than controlled trials.

TB-500 and the Thymosin Beta-4 Fragment

TB-500 is a synthetic analog of Thymosin Beta-4 (TB4), specifically the actin-binding domain fragment. TB4 is a 43-amino-acid protein involved in cell migration, angiogenesis, and tissue repair. [6]

Mechanism

TB4 promotes actin polymerization and has shown anti-inflammatory activity in preclinical models. A 2010 paper in the Annals of the New York Academy of Sciences described TB4's role in cardiac repair after myocardial infarction in rodents, with treated animals showing measurably reduced infarct size. [7]

Clinical Development

The TB4 fragment PDA-66 (formerly known as Ac-SDKP) has advanced further than BPC-157 in human trials. RegeneRx Biopharmaceuticals has conducted Phase 2 trials of TB4 for dry eye disease and cardiac indications. Results from the cardiac trial (N=73) showed a non-significant trend toward improved ejection fraction at 6 months. The trial was not powered to reach significance; it was exploratory. [8]

Huberman Context

Huberman has mentioned Thymosin Beta-4 in the context of injury recovery on his podcast. He described the compound's mechanism accurately, referencing its role in cytoskeletal dynamics. Whether he uses TB-500 specifically is not confirmed in any public statement reviewed for this article.

PT-141 (Bremelanotide): The One With an FDA Approval

PT-141 is worth treating separately because it is the only peptide in this discussion with an actual FDA approval. Sold as Vyleesi (bremelanotide injection, 1.75 mg/0.3 mL), it was approved by the FDA on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. [1]

How It Works

Bremelanotide is a melanocortin receptor agonist, acting primarily at MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on blood vessels, PT-141 acts centrally on desire pathways. [9] This distinction is one Huberman has made explicitly in his podcasts on sexual health.

Efficacy Data

The key trials (RECONNECT studies, combined N=1,247) showed that women using bremelanotide had a statistically significant increase in satisfying sexual events compared to placebo (P<0.001) and a reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). [10]

Off-Label Male Use

PT-141 is used off-label in men for erectile dysfunction and libido. No FDA-approved indication exists for males. Small pilot studies have examined melanocortin agonism in men, but no large RCT has been completed in a male population. Huberman's discussion of PT-141 referenced both sexes.

Growth-Hormone Secretagogues: CJC-1295 and Ipamorelin

INFERRED: Based on Huberman's detailed podcast discussions of GH secretagogue pharmacology, the following section covers the two compounds most commonly associated with the "GH pulse" protocol he has described. Neither is confirmed as part of his personal use.

CJC-1295 (a GHRH Analog)

CJC-1295 is a modified growth-hormone-releasing hormone analog with a half-life extended to approximately 6 to 8 days through a drug affinity complex (DAC) modification. Without the DAC modification (known as Mod GRF 1-29), the half-life drops to roughly 30 minutes. [11]

A 2006 study in the Journal of Clinical Endocrinology and Metabolism (N=65) found that CJC-1295 with DAC produced dose-dependent increases in mean GH concentrations of 2- to 10-fold above baseline across multiple doses from 30 mcg/kg to 120 mcg/kg, with IGF-1 increases of 1.5- to 3-fold sustained for 6 days. [12]

Ipamorelin (a Ghrelin Mimetic)

Ipamorelin is a selective GH secretagogue receptor agonist. It stimulates GH release with minimal effect on cortisol or prolactin, which distinguishes it from older secretagogues like GHRP-2 and GHRP-6 that carry more off-target activity. [13]

Preclinical data published in Growth Hormone and IGF Research showed that ipamorelin produced GH pulses in rats comparable to GHRP-6 but with significantly lower ACTH and cortisol elevation. [14]

The Stack Rationale

Combining a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) targets two separate steps in GH release, producing a synergistic pulse. Practitioners who use these compounds typically describe subcutaneous injection of 100 mcg to 300 mcg of each, administered before sleep to align with endogenous GH release during slow-wave sleep. No large-scale human RCT has validated this specific combination protocol.

Regulatory and Safety Considerations

The FDA classifies most peptides discussed in this article as unapproved new drugs when sold for human use outside a clinical trial. In March 2022, the FDA removed several peptides, including BPC-157 and TB-500, from the list of bulk drug substances eligible for compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. [5]

What This Means for Patients

Compounded peptides purchased outside an FDA-cleared framework carry meaningful risks.

• Purity: Independent analyses of commercially available peptides have found wide variation in actual peptide content versus label claims.
• Sterility: Subcutaneously injected compounds require sterile manufacturing conditions that are not guaranteed by non-503B compounders.
• Dosing accuracy: Without pharmacokinetic data in humans, dose-response relationships remain poorly defined.

Huberman himself has stated on his podcast that listeners should consult their physicians before using any compound he discusses. That caveat matters here. The gap between the mechanistic interest Huberman expresses and clinical readiness for human use is real for most of these compounds.

PT-141 as the Exception

Because bremelanotide (Vyleesi) is FDA-approved, a physician can prescribe it for its approved indication through standard pharmacy channels. Off-label prescribing for men is at the discretion of the treating physician and should follow standard informed-consent practices. The FDA label for Vyleesi notes nausea (in 40% of trial participants), flushing, and transient blood pressure increases as the primary adverse effects. [1]

How a HealthRX Physician Evaluates These Compounds

A board-certified physician reviewing a patient's interest in peptides would typically apply the following framework before making any prescribing decision.

Step 1: Confirm indication. Is there a documented condition (tendon injury, HSDD, GH deficiency) that the peptide might address? Off-label use without a clear indication raises the risk-benefit ratio.

Step 2: Review evidence tier. PT-141 has Phase 3 human RCT data and an FDA approval. CJC-1295 has Phase 2 human data. BPC-157 and TB-500 have only animal and preclinical data for most indications.

Step 3: Screen for contraindications. Melanocortin agonists (PT-141) are contraindicated in patients with uncontrolled hypertension. GH secretagogues are generally avoided in patients with active malignancy given IGF-1's mitogenic potential. [15]

Step 4: Source verification. If a peptide is prescribed, it should come from an FDA-registered 503B outsourcing facility where sterility and potency are tested.

Step 5: Monitoring. IGF-1 levels should be measured at baseline and at 8 weeks for anyone using GH secretagogues. A target IGF-1 in the upper quartile of the age-adjusted reference range (roughly 200 to 300 ng/mL for adults under 50) is a commonly cited goal, though no RCT has validated a specific target. [16]

What Huberman's Protocol Discussions Mean for the Field

Huberman's podcast reach, estimated at over 3 million downloads per episode, means that his discussions of peptides directly influence public demand for these compounds. A 2023 survey by the American Academy of Anti-Aging Medicine found that inquiries about BPC-157 and secretagogue stacks increased by over 40% in the two years following his earliest peptide-focused episodes. That figure has not been independently validated in a peer-reviewed publication and is noted here as context rather than evidence.

The more significant contribution may be Huberman's insistence on mechanistic literacy. His audiences arrive at physician consultations with unusually specific questions about receptor pharmacology. Whether that translates to better patient outcomes or to more pressure on physicians to prescribe outside evidence-based guidelines is an open question in clinical practice. The Endocrine Society's 2019 clinical practice guideline on growth hormone use in adults explicitly states that GH therapy should be reserved for patients with documented GH deficiency, defined as a peak stimulated GH response <3 ng/mL. [17]

That guideline does not address secretagogues directly, but its underlying principle applies: GH-axis manipulation without documented deficiency lacks a formal evidence base for long-term safety.